Successful ERP System Implementation
Embecta completed the implementation of its own ERP system and operationalized new distribution networks in Latin America and India, marking a major milestone in its multi-year standard program.
Advancement in GLP-1 Strategy
Embecta advanced its GLP-1 strategy by collaborating with over 30 pharmaceutical partners and began co-packaging its pen needles with generic GLP-1 therapies, targeting a $100 million annual revenue opportunity by 2033.
Debt Reduction and Financial Discipline
Embecta generated approximately $182 million in free cash flow and paid down $184 million of debt, exceeding its original target of $110 million, reducing leverage to 2.9 times net debt to adjusted EBITDA.
Adjusted Operating Margin Improvement
The adjusted operating margin improved to 25.3% in Q4 2025, compared to 21.1% in the prior year period, primarily due to lower R&D and SG&A expenses.
Revenue from Safety Products and Contract Manufacturing
Safety products revenue grew by 3.7% and contract manufacturing revenue increased by 8.5% during the fourth quarter.